Keyphrases
Renal Impairment
100%
Axitinib
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Estimated Glomerular Filtration Rate
83%
Renal Function
66%
Function Group
33%
Confidence Interval
16%
Renal Disease
16%
Hypertension
16%
Clinical Characteristics
16%
Prognostic Factors
16%
Treatment Initiation
16%
Objective Response Rate
16%
Adverse Events
16%
Progression-free Survival
16%
Median Progression-free Survival
16%
Chronic Kidney Disease
16%
Multicenter Cohort Study
16%
Urinary Disorders
16%
Treatment-related
16%
Limited Information
16%
Dialysis
16%
Risk of Progression
16%
End-stage Renal Disease
16%
Impaired Renal Function
16%
TKI Therapy
16%
Antiangiogenic Therapy
16%
VEGFR-TKI
16%
Baseline Renal Function
16%
Medicine and Dentistry
Kidney Function
100%
Kidney Metastasis
100%
Axitinib
100%
Glomerular Filtration Rate
83%
Progression Free Survival
33%
Disease
16%
Cohort Analysis
16%
Adverse Event
16%
Prognostic Factor
16%
Urinary System
16%
Vasculotropin
16%
Chronic Kidney Disease
16%
Clinician
16%
Antiangiogenic Therapy
16%
End Stage Renal Disease
16%
Post-Hoc Analysis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Metastasis
100%
Axitinib
100%
Progression Free Survival
33%
Chronic Kidney Failure
16%
Disease
16%
Adverse Event
16%
Vasculotropin
16%
Cohort Study
16%
End Stage Renal Disease
16%
Antiangiogenic Therapy
16%